SCYX SCYNEXIS, Inc. Company Cash Funds

Graphic logo of scynexis.com (SCYX)

SCYNEXIS, Inc. (SCYX) revenues are based on Brexafemme sales and payments from GSK. The cash balance illustrates the resource dynamics for operating activities, where 0.05 is the current level of this metric. Stability is ensured by exclusive patents for next-generation antimycotics. Minimal geopolitical risks and operations within the US legal framework guarantee the protection of intellectual property.

SCYX - SCYNEXIS Company Cash on Hand over the range 07/04/2022 - 11/21/2026

SCYNEXIS, Inc. (SCYX) - metric breakdowns and financial figures

- stock value and consensus price forecast:
Analysis of all company metrics:scynexis.com SCYX
Signature product of Scynexis

Fundamental asset selection requires precise liquidity monitoring to assess a business's ability to service its obligations without external financing. This indicator measures actual cash volume, determining the capital burn rate of SCYNEXIS, Inc. (SCYX) given its narrow specialization in a single platform, which allows for an assessment of the licensing model's sustainability via current cash reserves in the absence of operational growth.